The investigation of immunomodulatory effects of didemnin B in macrophage cells

Didemnins, which are cyclic depsipeptides originating from marine sources, have gained significant interest owing to their potent anti-cancer properties. Among them, Didemnin B exhibits potent anti-tumor effects; however, its poor bioavailability and dose-limiting toxicity have thus far restricted its clinical application. Understanding its immunological impact is therefore essential for optimizing its therapeutic potential and supporting ongoing efforts to develop Didemnin B as a clinically viable agent. This study aimed to investigate the immunomodulatory effects of Didemnin B on macrophage function, with a particular focus on its potential relevance to immunotherapeutic and chemotherapeutic applications. In this context, Didemnin B was applied at concentrations of 1, 5, and 10 µg/mL to RAW 264.7 macrophages, based on dose ranges previously reported in the literature. The production of TNF-α, IL-6, GM-CSF, and IL-12p40 was evaluated under both unstimulated and LPS-stimulated conditions. Cytokine levels in cell culture supernatants were measured using ELISA to assess how Didemnin B modulates macrophage cytokine responses. Our findings demonstrate that Didemnin B suppresses the production of TNF-α, IL-6, GM-CSF, and IL-12p40 in RAW 264.7 macrophages, indicating a robust inhibitory effect on pro-inflammatory cytokine secretion. Didemnin B significantly attenuates LPS-induced inflammatory responses in RAW 264.7 macrophages by suppressing key pro-inflammatory cytokines, indicating its potential as a potent anti-inflammatory and immunomodulatory agent.